Read by QxMD icon Read

Journal of Infectious Diseases

David Mesher, Kavita Panwar, Sara L Thomas, Claire Edmundson, Yoon Hong Choi, Simon Beddows, Kate Soldan
Background: The national human papillomavirus (HPV) immunization program was introduced in England in September 2008 using the bivalent vaccine. Methods: We collected residual vulva-vaginal swab specimens from 16 to 24-year-old women attending for chlamydia screening between 2010 and 2016 and tested for HPV DNA. We compared changes in type-specific (vaccine and nonvaccine) HPV prevalence over time and association with vaccination coverage. For women with known vaccination status, vaccine effectiveness was estimated...
June 18, 2018: Journal of Infectious Diseases
Manfred Weidmann, Ousmane Faye, Oumar Faye, Ahmed Abd El Wahed, Pranav Patel, Christophe Batejat, Jean Claude Manugerra, Aimee Adjami, Matthias Niedrig, Frank T Hufert, Amadou A Sall
Background: In order to enable local response to viral haemorrhagic fever outbreaks a mobile laboratory transportable on commercial flights was developed. Methodology: The development progressed from use of mobile real time RT-PCR to mobile Recombinase Polymerase Amplification (RT-RPA). The various stages of the mobile laboratory development are described. Results: A brief overview of its deployments, which culminated in the first on site detection of Ebola virus disease (EVD) in March 2014 and a successful use in a campaign to roll back EVD cases in Conakry in the West-Africa Ebola virus outbreak are described...
June 15, 2018: Journal of Infectious Diseases
Rodolfo D Vicetti Miguel, Nirk E Quispe Calla, Thomas L Cherpes
No abstract text is available yet for this article.
June 15, 2018: Journal of Infectious Diseases
Sergej Franz, Martina Friesland, Vânia Passos, Daniel Todt, Graham Simmons, Christine Goffinet, Eike Steinmann
Despite increasing clinical relevance of Chikungunya virus (CHIKV) infection, caused by a rapidly emerging pathogen, recommended guidelines for its inactivation do not exist. Here, we investigated the susceptibility of CHIKV to inactivation by heat and commercially available hand, surface and WHO-recommended disinfectants to define CHIKV prevention protocols for healthcare systems.
June 15, 2018: Journal of Infectious Diseases
Temet M McMichael, Yu Zhang, Adam D Kenney, Lizhi Zhang, Ashley Zani, Mijia Lu, Mahesh Chemudupati, Jianrong Li, Jacob S Yount
Human metapneumovirus (hMPV) utilizes a bifurcated cellular entry strategy, fusing either with the plasma membrane or, after endocytosis, with the endosome membrane. Whether cellular factors restrict or enhance either entry pathway is largely unknown. We found that the interferon-induced transmembrane protein 3 (IFITM3) inhibits hMPV infection to an extent similar to endocytosis-inhibiting drugs, and an IFITM3 variant that accumulates at the plasma membrane in addition to its endosome localization provided increased virus restriction...
June 15, 2018: Journal of Infectious Diseases
Kirk Haltaufderhyde, Anon Srikiatkhachorn, Sharone Green, Louis Macareo, Sangshin Park, Siripen Kalayanarooj, Alan L Rothman, Anuja Mathew
Follicular helper T cells (TFH) are specialized CD4 T cells required for B-cell help and antibody production. Given the postulated role of immune activation in dengue disease, we measured the expansion and activation of TFH in the circulation (pTFH) collected from Thai children with laboratory-confirmed acute DENV infection. We found significant expansion and activation of pTFH subsets during acute infection with the highest frequencies of activated pTFH (PD1hi pTFH and PD1+CD38+ pTFH) detected during the critical phase of illness...
June 15, 2018: Journal of Infectious Diseases
Hélène C F Côté, Anthony Y Y Hsieh
No abstract text is available yet for this article.
June 15, 2018: Journal of Infectious Diseases
Rocio Montejano, Natalia Stella-Ascariz, Susana Monge, José I Bernardino, Ignacio Pérez-Valero, Mª Luisa Montes, Eulalia Valencia, Luz Martín-Carbonero, Victoria Moreno, Juan González-Garcia, Javier Rodriguez-Centeno, Berta Rodes, Andres Esteban Cantos, Belen Alejos, Rosa de Miguel, Francisco Arnalich, Rosario Perona, José R Arribas
Background: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. Methods: Prospective cohort of HIV-1 infected participants with suppressed virological replication, comparing whole blood telomere length (measured by quantitative multiplex PCR) of participants with current exposure versus never exposed to tenofovir disoproxil fumarate. Results: 172 participants included: 67 in the tenofovir disoproxil fumarate (TDF)-group and 105 in the non-TDF group [75 receiving two nucleosides (69 abacavir), 25 receiving a completely nucleos(t)ide sparing regimen, and 5 receiving lamivudine as the only nucleoside]...
June 15, 2018: Journal of Infectious Diseases
Olivier Escaffre, Terence Hill, Tetsuro Ikegami, Terry L Juelich, Jennifer K Smith, Lihong Zhang, David E Perez, Colm Atkins, Arnold Park, William S Lawrence, Satheesh K Sivasubramani, Jennifer E Peel, Johnny W Peterson, Benhur Lee, Alexander N Freiberg
Background: Nipah virus (NiV) is a paramyxovirus (genus henipavirus) that can cause severe respiratory illness and encephalitis in humans. Transmission occurs through consumption of NiV-contaminated foods, and contact with NiV-infected animals or human body fluids. However, it is unclear whether aerosols derived from aforesaid sources or others also contribute to transmission, and current knowledge on NiV-induced pathogenicity after small particle aerosol exposure is still limited. Methods: infectivity, pathogenicity and real-time dissemination of aerosolized NiV in Syrian hamsters was evaluated using NiV-Malaysia (NiV-M) and/or its recombinant expressing firefly luciferase (rNiV-Fluc NP)...
June 15, 2018: Journal of Infectious Diseases
Zhilei Shan, Clary B Clish, Simin Hua, Justin M Scott, David B Hanna, Robert D Burk, Sabina A Haberlen, Sanjiv J Shah, Joseph B Margolick, Cynthia L Sears, Wendy S Post, Alan L Landay, Jason M Lazar, Howard N Hodis, Kathryn Anastos, Robert C Kaplan, Qibin Qi
We examined associations of 5 plasma choline metabolites with carotid plaque among 520 HIV-infected and 217 HIV-uninfected participants (112 incident plaque cases) over 7 years. After multivariable adjustment, higher gut microbiota-related metabolite trimethylamine-N-oxide (TMAO) was associated with an increased risk of carotid plaque in HIV-infected participants (risk ratio=1.25 [95% CI, 1.05-1.50] per standard deviation increment; P=0.01). TMAO was positively correlated with biomarkers of monocyte activation and inflammation (sCD14, sCD163)...
June 15, 2018: Journal of Infectious Diseases
Ping An, Zheng Zeng, Cheryl A Winkler
Background: Sodium taurocholate cotransporting polypeptide (NTCP, SLC10A1) was recently identified as a hepatocyte receptor for infection of Hepatitis B virus (HBV). The natural S267F variant in NTCP causes a loss of HBV receptor function of NTCP. Objective: We assessed the association of S267F with HBV resistance, HBV infection clearance, and HBV-related cirrhosis and HCC. Methods: We tested the effects of S267F in 1117 Han Chinese patients with various HBV infection outcomes using multivariate logistic regression analysis...
June 14, 2018: Journal of Infectious Diseases
Anna Godi, Marianna Martinelli, Mahmoud Haque, Shaowei Li, Qinjian Zhao, Ningshao Xia, Clementina E Cocuzza, Simon Beddows
Background: Naturally-occurring variants of Human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known about the impact of this diversity on protein function. We investigate the impact of variation within the major (L1) and minor (L2) capsid proteins of HPV58 on susceptibility to neutralizing antibodies. Methods: Pseudovirus (PsV) representing A1, A2, A3, B1, B2, C, D1 and D2 variants were evaluated for their susceptibility to antibodies elicited during natural infection, preclinical antisera generated against virus-like particles and monoclonal antibodies (MAbs)...
June 13, 2018: Journal of Infectious Diseases
Jacqueline S Stevens, Mary C Gray, Christophe Morisseau, Alison K Criss
Background: Infection with Neisseria gonorrhoeae (Ngo) is characterized by robust neutrophil influx that is insufficient to clear the bacteria. Sustained neutrophilic inflammation contributes to serious clinical sequelae that particularly affect women, including pelvic inflammatory disease and infertility. Methods: We established a three-component system using Ngo, End1 polarized human endocervical cells, and primary human neutrophils to investigate neutrophil transepithelial migration following infection...
June 13, 2018: Journal of Infectious Diseases
Jacqueline J Janse, Marijke C C Langenberg, Janneke Kos-Van Oosterhoud, Arifa Ozir-Fazalalikhan, Eric A T Brienen, Béatrice M F Winkel, Marianne A A Erkens, Martha T van der Beek, Lisette van Lieshout, Hermelijn H Smits, Bonnie L Webster, Maarten L Zandvliet, Richard Verbeek, Inge M Westra, Pauline Meij, Leo G Visser, Angela van Diepen, Cornelis H Hokke, Maria Yazdanbakhsh, Meta Roestenberg
To accelerate the development of novel vaccines for schistosomiasis, we set out to develop a human model for Schistosoma mansoni infection in healthy volunteers. During natural infections, female schistosomes produce eggs that give rise to morbidity. Therefore, we produced single-sex, male Schistosoma mansoni cercariae for human infection without egg production and associated pathology. Cercariae were produced in their intermediate snail hosts in accordance with the principles of good manufacturing practice (GMP)...
June 13, 2018: Journal of Infectious Diseases
Christoph Höner Zu Siederdissen, Aric Josun Hui, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Wei Wen Su, Gerardo Enrique Guillén Nieto, Paul Gineste, Josianne Nitcheu, Sandrine Crabé, Sandrine Stepien, Michael P Manns, Christian Trépo, Heiner Wedemeyer, Markus Cornberg
Stopping long-term nucleos(t)ide analogue therapy increases HBsAg loss rates in HBeAg-negative patients. Viral rebound may induce immune responses facilitating functional cure. We analyzed which factors are associated with timing of virological relapse in 220 Asian HBeAg-negative patients from the prospective ABX203 vaccine study. Unexpectedly, only the type of antiviral therapy was significantly associated with early virological relapse, defined as HBV DNA > 2,000 IU/ml until week 12 and occurred earlier in patients treated with tenofovir versus entecavir (median time 6 versus 24 weeks, p < 0...
June 9, 2018: Journal of Infectious Diseases
Mangala Rao, Sayali Onkar, Kristina K Peachman, Yohann White, Hung V Trinh, Ousman Jobe, Yingjun Zhou, Peter Dawson, Michael A Eller, Gary R Matyas, Carl R Alving
Background: In the RV144 trial, HIV-1 gp120 V1V2 antibodies correlated inversely with risk of HIV-1 infection; however the titers waned quickly. We hypothesized that a more potent adjuvant might enhance the magnitude and durability of V1V2 antibodies. Methods: We examined archived sera from a phase I randomized, double blind placebo-controlled trial, conducted in HIV-1 uninfected individuals, vaccinated with HIV-1SF-2 rgp120 either adsorbed to aluminum hydroxide (aluminum hydroxide arm) or encapsulated in liposomes containing monophosphoryl lipid A (MPL®) and then adsorbed to aluminum hydroxide (liposomal arm)...
June 9, 2018: Journal of Infectious Diseases
Ying Liu, Ling Ye, Fang Lin, Yasmine Gomaa, David Flyer, Ricardo Carrion, Jean L Patterson, Mark R Prausnitz, Gale Smith, Gregory Glenn, Hua Wu, Richard W Compans, Chinglai Yang
In this study, we investigated immune responses induced by purified Ebola virus (EBOV) soluble glycoprotein (sGP) subunit vaccines via intradermal immunization with microneedle (MN) patches in comparison with intramuscular (IM) injection in mice. Our results showed that MN delivery of EBOV sGP was superior to IM injection in eliciting higher levels and longer lasting antibody responses against EBOV sGP and GP antigens. Moreover, sGP-specific immune responses induced by MN or IM immunizations were effectively augmented by formulating sGP with a saponin-based adjuvant, and they were shown to confer complete protection of mice against lethal mouse-adapted EBOV (MA-EBOV) challenge...
June 8, 2018: Journal of Infectious Diseases
Gary Wong, Zirui Zhang, Shihua He, Marc-Antoine de La Vega, Kevin Tierney, Geoff Soule, Kaylie Tran, Lisa Fernando, Xiangguo Qiu
Ferrets are used for studying infections with wild-type Ebola virus isolates. Here, we investigated whether these animals are also susceptible to wild-type isolates of Marburg virus (MARV). Ferrets were challenged intramuscularly or intranasally with MARV strain Angola and monitored for 3 weeks. Unexpectedly, the animals neither showed observable signs of disease nor died of infection, and viremia was not detected after challenge. All animals were seropositive for MARV-specific immunoglobulin antibodies. Confirmatory studies with MARV strain Musoke and Ravn virus yielded the same outcomes...
June 8, 2018: Journal of Infectious Diseases
Katendi Changula, Masahiro Kajihara, Akina Mori-Kajihara, Yoshiki Eto, Hiroko Miyamoto, Reiko Yoshida, Asako Shigeno, Bernard Hang'ombe, Yongjin Qiu, Daniel Mwizabi, David Squarre, Joseph Ndebe, Hirohito Ogawa, Hayato Harima, Edgar Simulundu, Ladslav Moonga, Penjaninge Kapila, Wakako Furuyama, Tatsunari Kondoh, Masahiro Sato, Yoshihiro Takadate, Chiho Kaneko, Ryo Nakao, Victor Mukonka, Aaron Mweene, Ayato Takada
Bats are suspected to play important roles in the ecology of filoviruses, including ebolaviruses and marburgviruses. A cave-dwelling fruit bat, Rousettus aegyptiacus, has been shown to be a reservoir of marburgviruses. Using an enzyme-linked immunosorbent assay with the viral glycoprotein antigen, we detected immunoglobulin G antibodies specific to multiple filoviruses in 158 of 290 serum samples of R aegyptiacus bats captured in Zambia during the years 2014-2017. In particular, 43.8% of the bats were seropositive to marburgvirus, supporting the notion that this bat species continuously maintains marburgviruses as a reservoir...
June 8, 2018: Journal of Infectious Diseases
Andrea Marzi, Elaine Haddock, Masahiro Kajihara, Heinz Feldmann, Ayato Takada
Marburg virus (MARV), family Filoviridae, causes Marburg hemorrhagic fever (MHF) in humans and nonhuman primates with case fatality rates of up to 90%. There is no approved therapeutic for MHF, yet several experimental approaches have been evaluated in preclinical studies including small interfering RNA and monoclonal antibody (mAb) treatment. In this study we attempted to improve the therapeutic efficacy of the neutralizing mAb M4 by combining treatment with 1 or 2 of blocking but nonneutralizing mAbs 126-15 and 127-8...
June 8, 2018: Journal of Infectious Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"